Jergin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jergin Chen has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Dennis C. Shrieve
From the Department of Radiation Oncology, Huntsman Cancer Institute, Salt Lake City, Utah
4 shared publications- Jonathan David Tward
Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
3 shared publications Brandon G. Bentz
Department of Otolaryngology University of Utah
2 shared publicationsDavid K. Gaffney
2 shared publicationsJohn K. Hayes
Department of Radiation Oncology University of Utah Salt Lake City UT
2 shared publicationsLisa Pappas
Department of Biostatistics Core Huntsman Cancer Institute Salt Lake City UT
2 shared publications
Latest Publications
- 1 July 2013
- Published by Elsevier in Cancer Letters
- Vol. 335 (1) , 214-218
Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy
- 1 July 2013
- Published by Elsevier in Cancer Letters
- Vol. 335 (1) , 214-218
Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy
- 1 August 2009
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 32 (4) , 411-416
Prognostic Significance of Histology and Positive Lymph Node Involvement Following Radical Hysterectomy in Carcinoma of the Cervix
Lymph node (LN) metastasis portends a poor outcome in women with carcinoma of the uterine cervix. We queried a large database to analyze the importance of number of positive LN and histology in relation to survival after radical hysterectomy and lymphadenectomy. Data were collected from the Surveillance, Epidemiology, and End Results Program on women who had primary surgery for the years 1988 to 2003 (n = 4559). Statistical analyses were performed using conventional methods. The median number of LNs examined per patient has significantly declined in recent years (P = 0.003). The 5-year rates of cause specific and overall survival were 94% and 91%, 76% and 69%, 62% and 58%, and 41% and 35%, for 0, 1 to 2, 3 to 9 and ≥10 positive LNs, respectively. Pathologic LN involvement was associated with higher grade, higher stage, larger tumor size, and squamous cell histology. Predictors for both cause specific and overall survival on multivariate analysis included number of involved LN, histology, tumor grade, tumor size, disease stage, and pelvis or paraaortic lymphatic involvement. Adenocarcinoma histology independently predicted for a more aggressive phenotype, particularly in women with LN involvement. The number of LNs examined did not independently predict for survival when adjusted for patient and disease characteristics, providing context for the investigation of sentinel node biopsy or other sampling methods. LN positive disease in carcinoma of the cervix predicts a prognosis that is inversely related to the number of involved nodes. Tumor grade, size, and FIGO stage were associated with increasing risk for lymph node metastases.
- 1 August 2009
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 32 (4) , 411-416
Prognostic Significance of Histology and Positive Lymph Node Involvement Following Radical Hysterectomy in Carcinoma of the Cervix
Lymph node (LN) metastasis portends a poor outcome in women with carcinoma of the uterine cervix. We queried a large database to analyze the importance of number of positive LN and histology in relation to survival after radical hysterectomy and lymphadenectomy. Data were collected from the Surveillance, Epidemiology, and End Results Program on women who had primary surgery for the years 1988 to 2003 (n = 4559). Statistical analyses were performed using conventional methods. The median number of LNs examined per patient has significantly declined in recent years (P = 0.003). The 5-year rates of cause specific and overall survival were 94% and 91%, 76% and 69%, 62% and 58%, and 41% and 35%, for 0, 1 to 2, 3 to 9 and ≥10 positive LNs, respectively. Pathologic LN involvement was associated with higher grade, higher stage, larger tumor size, and squamous cell histology. Predictors for both cause specific and overall survival on multivariate analysis included number of involved LN, histology, tumor grade, tumor size, disease stage, and pelvis or paraaortic lymphatic involvement. Adenocarcinoma histology independently predicted for a more aggressive phenotype, particularly in women with LN involvement. The number of LNs examined did not independently predict for survival when adjusted for patient and disease characteristics, providing context for the investigation of sentinel node biopsy or other sampling methods. LN positive disease in carcinoma of the cervix predicts a prognosis that is inversely related to the number of involved nodes. Tumor grade, size, and FIGO stage were associated with increasing risk for lymph node metastases.
- 1 October 2008
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 31 (5) , 460-464
Surgery and Radiotherapy Improves Survival in Patients With Anaplastic Thyroid Carcinoma
Objectives: Anaplastic thyroid carcinoma is associated with a high rate of local recurrence and poor prognosis. This analysis examines the effects of surgery and radiotherapy on survival. Methods and Materials: Anaplastic thyroid carcinoma patients from the Surveillance, Epidemiology, and End Results database from 1983 to 2002 with ≥1-month survival after diagnosis who either had surgery performed or recommended were included in the analysis. Results: Two hundred sixty-one patients met the inclusion criteria for analysis. Median survival was 4 months. Distant or metastatic disease, tumor size >7 cm, and treatment with surgery plus or minus radiotherapy were statistically significant as prognostic for survival on multivariate analysis (P < 0.05). When stratified by extent of disease, the addition of radiotherapy to surgery resulted in improved survival for patients with disease extending into adjacent tissue (P = 0.05); however, patients who had disease confined to the capsule or had further extension or distant metastatic disease did not benefit from radiotherapy after surgery (P > 0.05). Conclusions: Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma. Aggressive treatment with surgery and chemoradiation should be encouraged.
- 1 October 2008
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 31 (5) , 460-464
Surgery and Radiotherapy Improves Survival in Patients With Anaplastic Thyroid Carcinoma
Objectives: Anaplastic thyroid carcinoma is associated with a high rate of local recurrence and poor prognosis. This analysis examines the effects of surgery and radiotherapy on survival. Methods and Materials: Anaplastic thyroid carcinoma patients from the Surveillance, Epidemiology, and End Results database from 1983 to 2002 with ≥1-month survival after diagnosis who either had surgery performed or recommended were included in the analysis. Results: Two hundred sixty-one patients met the inclusion criteria for analysis. Median survival was 4 months. Distant or metastatic disease, tumor size >7 cm, and treatment with surgery plus or minus radiotherapy were statistically significant as prognostic for survival on multivariate analysis (P < 0.05). When stratified by extent of disease, the addition of radiotherapy to surgery resulted in improved survival for patients with disease extending into adjacent tissue (P = 0.05); however, patients who had disease confined to the capsule or had further extension or distant metastatic disease did not benefit from radiotherapy after surgery (P > 0.05). Conclusions: Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma. Aggressive treatment with surgery and chemoradiation should be encouraged.
- 1 June 2008
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 111 (6) , 1394-1402
Incidence, Mortality, and Prognostic Factors of Small Cell Carcinoma of the Cervix
OBJECTIVE: To compare the incidence, mortality, and presentation of small cell carcinoma of the cervix with other histologies. METHODS: From 1977 to 2003, 290 women with small cell carcinoma of the cervix uteri were identified from the Surveillance, Epidemiology, and End Results database. Also, 27,527 patients with squamous cell carcinoma of the cervix and 5,231 patients with adenocarcinoma of the cervix were identified for comparison. The annual incidence was calculated and examined for trend. Patient and disease characteristics were compared among histologies. Univariable analyses were conducted using the log-rank test. Multivariable analysis was performed using Cox regression. RESULTS: The mean annual incidence for small cell carcinoma was 0.06 per 100,000 women, compared with 6.6 and 1.2 for squamous cell carcinoma and adenocarcinoma, respectively. There were significant differences at presentation between small cell carcinoma compared with squamous cell carcinoma and adenocarcinoma for race, treatment, International Federation of Gynecology and Obstetrics stage, and lymph node involvement ( P <.05). A trend for improved survival was identified for adenocarcinoma ( P =.036) and squamous cell carcinoma ( P <.001) but not for small cell carcinoma ( P =.672). Five-year survival for small cell carcinoma (35.7%) was worse compared with squamous cell carcinoma (60.5%, hazard ratio 0.55; 95% confidence interval (CI) 0.43–0.69) and adenocarcinoma (69.7%, hazard ratio 0.48; 95% CI 0.37–0.61). On multivariable analysis, age, stage, and race were prognostic for survival in women with small cell carcinoma ( P <.05). CONCLUSION: Small cell carcinoma is a rare histology of cervical cancer associated with a worse prognosis and a predilection for nodal and distant metastasis. The decrease in survival was marked in early-stage and node-negative patients. Because of the high rates of nodal involvement even with early-stage disease, multimodality treatment with radiotherapy and chemotherapy should be considered. LEVEL OF EVIDENCE: II
- 1 June 2008
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 111 (6) , 1394-1402
Incidence, Mortality, and Prognostic Factors of Small Cell Carcinoma of the Cervix
OBJECTIVE: To compare the incidence, mortality, and presentation of small cell carcinoma of the cervix with other histologies. METHODS: From 1977 to 2003, 290 women with small cell carcinoma of the cervix uteri were identified from the Surveillance, Epidemiology, and End Results database. Also, 27,527 patients with squamous cell carcinoma of the cervix and 5,231 patients with adenocarcinoma of the cervix were identified for comparison. The annual incidence was calculated and examined for trend. Patient and disease characteristics were compared among histologies. Univariable analyses were conducted using the log-rank test. Multivariable analysis was performed using Cox regression. RESULTS: The mean annual incidence for small cell carcinoma was 0.06 per 100,000 women, compared with 6.6 and 1.2 for squamous cell carcinoma and adenocarcinoma, respectively. There were significant differences at presentation between small cell carcinoma compared with squamous cell carcinoma and adenocarcinoma for race, treatment, International Federation of Gynecology and Obstetrics stage, and lymph node involvement ( P <.05). A trend for improved survival was identified for adenocarcinoma ( P =.036) and squamous cell carcinoma ( P <.001) but not for small cell carcinoma ( P =.672). Five-year survival for small cell carcinoma (35.7%) was worse compared with squamous cell carcinoma (60.5%, hazard ratio 0.55; 95% confidence interval (CI) 0.43–0.69) and adenocarcinoma (69.7%, hazard ratio 0.48; 95% CI 0.37–0.61). On multivariable analysis, age, stage, and race were prognostic for survival in women with small cell carcinoma ( P <.05). CONCLUSION: Small cell carcinoma is a rare histology of cervical cancer associated with a worse prognosis and a predilection for nodal and distant metastasis. The decrease in survival was marked in early-stage and node-negative patients. Because of the high rates of nodal involvement even with early-stage disease, multimodality treatment with radiotherapy and chemotherapy should be considered. LEVEL OF EVIDENCE: II
- 1 May 2008
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 87 (2) , 274-280
Comparison of cervical esophagus dose-volumes for three radiotherapy techniques for head and neck cancer
- 1 May 2008
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 87 (2) , 274-280
Comparison of cervical esophagus dose-volumes for three radiotherapy techniques for head and neck cancer
- Open Access
- 1 February 2008
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 93 (2) , 504-515
The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer
Background: The 10-yr survival rate of patients with differentiated thyroid cancer exceeds 90%. These patients may be at elevated risk for secondary cancers. Methods: The risk of nonthyroid second primary malignancies after differentiated thyroid cancer was determined in 30,278 patients diagnosed between 1973 and 2002 from centers participating in the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. Median follow-up was 103 months (range, 2–359 months). Risk was further assessed for the addition of radioisotope therapy, gender, latency to development of secondary cancer, and age at thyroid cancer diagnosis. Results: There were 2158 patients who developed a total of 2338 nonthyroid second primary malignancies, significantly more than that expected in the general population [observed/expected (O/E) = 1.09; 95% confidence interval (CI), 1.05–1.14; P < 0.05; absolute excess risk per 10,000 person-years (AER) = 6.39]. A significantly greater risk of second primary malignancies over that expected in the general population was for patients treated with radioisotopes (O/E = 1.20; 95% CI, 1.07–1.33; AER = 11.8) as well as for unirradiated patients (O/E = 1.05; 95% CI, 1.00–1.10; AER = 3.53). However, the increased risk was greater for the irradiated vs. the unirradiated cohort (relative risk = 1.16; 95% CI, 1.05–1.27; P < 0.05). Gender did not affect risk. The greatest risk of second primary cancers occurred within 5 yr of diagnosis and was elevated for younger patients. Conclusions: The overall risk of second primary malignancies is increased for thyroid cancer survivors and varies by radioisotope therapy, latency, and age at diagnosis.
- 1 February 2008
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 93 (2) , 504-515
Open AccessThe Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer
Background: The 10-yr survival rate of patients with differentiated thyroid cancer exceeds 90%. These patients may be at elevated risk for secondary cancers. Methods: The risk of nonthyroid second primary malignancies after differentiated thyroid cancer was determined in 30,278 patients diagnosed between 1973 and 2002 from centers participating in the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. Median follow-up was 103 months (range, 2–359 months). Risk was further assessed for the addition of radioisotope therapy, gender, latency to development of secondary cancer, and age at thyroid cancer diagnosis. Results: There were 2158 patients who developed a total of 2338 nonthyroid second primary malignancies, significantly more than that expected in the general population [observed/expected (O/E) = 1.09; 95% confidence interval (CI), 1.05–1.14; P < 0.05; absolute excess risk per 10,000 person-years (AER) = 6.39]. A significantly greater risk of second primary malignancies over that expected in the general population was for patients treated with radioisotopes (O/E = 1.20; 95% CI, 1.07–1.33; AER = 11.8) as well as for unirradiated patients (O/E = 1.05; 95% CI, 1.00–1.10; AER = 3.53). However, the increased risk was greater for the irradiated vs. the unirradiated cohort (relative risk = 1.16; 95% CI, 1.05–1.27; P < 0.05). Gender did not affect risk. The greatest risk of second primary cancers occurred within 5 yr of diagnosis and was elevated for younger patients. Conclusions: The overall risk of second primary malignancies is increased for thyroid cancer survivors and varies by radioisotope therapy, latency, and age at diagnosis.
- 1 September 2007
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 137 (3) , 422-427
Planned Neck Dissection after Definitive Radiotherapy or Chemoradiation for Base of Tongue Cancers
OBJECTIVES: The study goal was to analyze the role of planned neck dissection for squamous cell carcinoma of the base of the tongue treated with definitive radiotherapy or chemoradiation.STUDY DESIGN, SETTING: We conducted a retrospective study of patients with squamous cell carcinoma of the base of the tongue undergoing planned neck dissection after definitive radiotherapy or chemoradiation.RESULTS: Twenty‐two of 41 (53.7%) patients had one to six positive residual lymph nodes after receiving definitive radiotherapy or chemoradiation. Neck control rates were 92.3% and 88.3% at two and five years, respectively. Three of 22 (13.6%) patients with pathological residual nodal disease had regional or locore‐gional failures, compared with 1 of 19 (5.3%) patients with a pathologically complete response (P = 0.39).CONCLUSIONS: We observed a high incidence of pathologically residual lymph nodes after definitive radiotherapy or chemoradiation.SIGNIFICANCE: Planned neck dissection following definitive radiotherapy or chemoradiation is highly effective in achieving regional control of squamous cell carcinoma of the base of the tongue.
- 1 September 2007
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 137 (3) , 422-427
Planned Neck Dissection after Definitive Radiotherapy or Chemoradiation for Base of Tongue Cancers
OBJECTIVES: The study goal was to analyze the role of planned neck dissection for squamous cell carcinoma of the base of the tongue treated with definitive radiotherapy or chemoradiation.STUDY DESIGN, SETTING: We conducted a retrospective study of patients with squamous cell carcinoma of the base of the tongue undergoing planned neck dissection after definitive radiotherapy or chemoradiation.RESULTS: Twenty‐two of 41 (53.7%) patients had one to six positive residual lymph nodes after receiving definitive radiotherapy or chemoradiation. Neck control rates were 92.3% and 88.3% at two and five years, respectively. Three of 22 (13.6%) patients with pathological residual nodal disease had regional or locore‐gional failures, compared with 1 of 19 (5.3%) patients with a pathologically complete response (P = 0.39).CONCLUSIONS: We observed a high incidence of pathologically residual lymph nodes after definitive radiotherapy or chemoradiation.SIGNIFICANCE: Planned neck dissection following definitive radiotherapy or chemoradiation is highly effective in achieving regional control of squamous cell carcinoma of the base of the tongue.
- 12 December 2006
- Published by Wiley in Head & Neck
- Vol. 29 (4) , 362-369
Treatment of oropharyngeal squamous cell carcinoma with external beam radiation combined with interstitial brachytherapy
Background. We reviewed the outcomes of oropharyngeal squamous cell carcinoma treated with external beam radiation and interstitial brachytherapy. Methods. Ninety patients with squamous cell carcinoma of the oropharynx were treated with interstitial brachytherapy at the University of Utah between 1984 and 2001. Seventy-two patients received external beam radiotherapy (EBRT) followed by brachytherapy boost, 11 had surgery followed by EBRT and brachytherapy, 4 had surgery and brachytherapy, and 3 were treated with brachytherapy alone. Median doses for EBRT and brachytherapy were 50 and 24 Gy, respectively. Results. Median follow-up after brachytherapy was 48.3 months for all patients. Five-year local control, disease-free survival, and overall survival were 76%, 61%, and 55%. For T1, T2, T3, and T4, 5-year local control rates were 83%, 79%, 79%, and 64%, respectively. Severe complications occurred in 13 patients, including 2 treatment-related deaths. Conclusions. EBRT combined with interstitial brachytherapy provide good local control rates for locally advanced oropharyngeal squamous cell carcinoma. © 2006 Wiley Periodicals, Inc. Head Neck, 2007.
- 12 December 2006
- Published by Wiley in Head & Neck
- Vol. 29 (4) , 362-369
Treatment of oropharyngeal squamous cell carcinoma with external beam radiation combined with interstitial brachytherapy
Background. We reviewed the outcomes of oropharyngeal squamous cell carcinoma treated with external beam radiation and interstitial brachytherapy. Methods. Ninety patients with squamous cell carcinoma of the oropharynx were treated with interstitial brachytherapy at the University of Utah between 1984 and 2001. Seventy-two patients received external beam radiotherapy (EBRT) followed by brachytherapy boost, 11 had surgery followed by EBRT and brachytherapy, 4 had surgery and brachytherapy, and 3 were treated with brachytherapy alone. Median doses for EBRT and brachytherapy were 50 and 24 Gy, respectively. Results. Median follow-up after brachytherapy was 48.3 months for all patients. Five-year local control, disease-free survival, and overall survival were 76%, 61%, and 55%. For T1, T2, T3, and T4, 5-year local control rates were 83%, 79%, 79%, and 64%, respectively. Severe complications occurred in 13 patients, including 2 treatment-related deaths. Conclusions. EBRT combined with interstitial brachytherapy provide good local control rates for locally advanced oropharyngeal squamous cell carcinoma. © 2006 Wiley Periodicals, Inc. Head Neck, 2007.
- 1 April 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 58 (5) , 1474-1479
Does radiotherapy around the time of pregnancy for Hodgkin's disease modify the risk of breast cancer?*1
- 1 April 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 58 (5) , 1474-1479
Does radiotherapy around the time of pregnancy for Hodgkin's disease modify the risk of breast cancer?*1